Big plans for 2016

Here is our CCFA January 2016 Newsletter. So we are KICK Starting our 2016 with ALL the happenings taking place in our CCFA Community with a Letter from our President & CEO First, thank you so much to everyone who helped us meet our holiday match! The funds you contributed will make a huge difference in the year ahead … because we have big plans for 2016. We are committed to expanding our mission activities, and will be introducing a host of innovative programs designed to serve our patients and improve their quality of life. We would also like to thank all of our President Corporate Circle members for their continued support of CCFA's mission: AbbVie, Allergan, Celgene Corporation, Genentech Inc., Gilead Sciences Inc., Immune Pharmaceuticals Inc., Janssen Biotech Inc., Pfizer Inc., Prometheus Laboratories Inc., Receptos, RedHill Biopharma, Salix Pharmaceuticals Inc., Shire, and Takeda Pharmaceuticals U.S.A. Inc. I am incredibly excited to be starting my first full year as President & CEO with all of you as my partners. I know, together, we will continue to do impactful and crucial things to serve the IBD community. Richard J. Geswell, CCFA President and CEO Thank you again! Michael Osso Michael Osso President & CEO Take Steps with Tyler "I want to be a doctor in San Diego someday so I can help sick kids get better." Tyler, a honored hero Every day, Take Steps and CCFA inspire children like Tyler to overcome the challenges of living with IBD. Will you please join us this year? Invite your friends, family, and co-workers to form a team and raise funds for cures. READ MORE ► What Exactly is Camp Oasis? Camp Oasis is a co-ed residential summer camp program that enriches the lives of children with IBD by providing them with a safe and supportive community. Since all of the kids (and many of the adults) are living with IBD, our camps allow them to see that they are not alone, try all sorts of new sports and activities, and create friendships with people who truly understand them. REGISTER TODAY ► An Iron Will A year ago, Brian's only goal was to be strong enough to get out of bed after his surgery. This year, he completed a half IRONMAN with an ostomy. It was one of the most emotional moments of his life—one that he will never forget. And even though he was faced with constant mental hurdles, he realized that Crohn's actually prepared him for all of it. Today, he encourages other IBD patients to create a goal of their own. READ MORE ► Be There for People with IBD With your help, we can continue to fund groundbreaking IBD research, as well as provide education and support services to hundreds of thousands of patients across the United States. Donate now A New Scholarship for IBD Patients! AbbVie has just launched a brand new scholarship fund to provide financial support to 15 exceptional students living with IBD as they pursue their higher education goals. It's just one of many scholarships available to IBD patients, so please visit our website for more information or call CCFA's IBD Help Center. READ MORE ► A Game-changer for IBD Research For the first time ever, more than 40,000 IBD patients, researchers, and healthcare providers will be brought together by IBD Plexus® to create the world’s largest registry of IBD patients of all ages, which will transform how Crohn's and colitis research is conducted. LEARN MORE ► Miss a Webcast? Not to worry! They are now available 24/7 on various topics, including: nutrition in IBD, complementary and alternative therapies, diagnostics in managing IBD, and updates in research. START WATCHING TODAY ► Search our resources Find your chapter IBD Clinical Trials and Other Studies CCFA provides a comprehensive database of studies, clinical trials and other research on Crohn's disease and ulcerative colitis. Some of the recently added studies include: A long-term registry to assess the safety and effectiveness of Humira in UC patients A study to evaluate Vedolizumab IV compared to Adalimumab SC in UC patients A trial to assess endoscopic improvement and changes in intestinal and serum biomarkers in Crohn’s patients receiving Oral RPC1063 A study looking at bacterial transmission in utero and IBD risk (The MECONIUM Study) Deciding whether to participate in a clinical trial is an important personal decision, best made with a full understanding of the drug development process and a participant's role. Team Challenge CCFA Facebook CCFA Twitter CCFA YouTube CCFA Pinterest Forward Donate to CCFA Crohn's and Colitis Foundation of America 7​33 Th​ird Av​en​ue, Sui​te 51​0, Ne​w Y​ork,​ N​Y 10​01​7 www.ccfa.org | 8​00-​93​2-​2​423 Talk with an I​BD Info​rmation Specialist at 88​8.M​y.Gu​t.P​ain | 8​88-​69​4-8​87​2